In older patients, rosiglitazone was associated with increased risk for stroke, heart failure, and mortality compared with pioglitazone: Commentary

Annals of Internal Medicine

Volumn 153, Issue 12, 2010, Pages

  Wang, Amy T ^a   Smith, Steven A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE;

ACUTE HEART INFARCTION; AGED; CONTROLLED STUDY; DRUG FATALITY; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NOTE; PRIORITY JOURNAL; RISK FACTOR; STROKE;

EID: 78751627542     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-153-12-201012210-02011     Document Type: Note

References (5)

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-71. (Pubitemid 46919772)
2. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125-35.
3. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA. 2007;298:1180-8. (Pubitemid 47403104)
4. Woodcock J. Decision on continued marketing of rosiglitazone (Avandia, Avandamet, Avandaryl). 22 Sep 2010. www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM226959.pdf (accessed 8 Oct 2010).
5. ClinicalTrials.gov. Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE). October 2010. www.clinicaltrials.gov/ct2/show/NCT00879970 (accessed 8 Oct 2010).